Last reviewed · How we verify
LAM-002A
At a glance
| Generic name | LAM-002A |
|---|---|
| Also known as | apilimod dimesylate |
| Sponsor | OrphAI Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis (PHASE2)
- A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (PHASE1)
- A Study of LAM-002A for the Prevention of Progression of COVID-19 (PHASE2)
- An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAM-002A CI brief — competitive landscape report
- LAM-002A updates RSS · CI watch RSS
- OrphAI Therapeutics portfolio CI